---
title: "Descartes-08 in Generalized myasthenia gravis: Pharmacokinetics"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Pharmacokinetics. Topics: Duration of CAR expression: about 1 week in vitro, Circulating CAR RNA after infusion: phase 1b/2a, Circulating CAR RNA after infusion and at month 3: phase 2b, and CAR expression in circulating T cells one day after infusion in a mouse xenograft model. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Duration of CAR expression: about 1 week in vitro

> “Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs.”
> “The expression of BCMA CAR on Descartes-08 cells was sustained for approximately 1 week, and gradually declined until 9 days (9d) after thawing following their generation (Fig. 1c).”

Source: [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)

<a id="topic-2.1.2.6.3-2"></a>

### Circulating CAR RNA after infusion: phase 1b/2a

> “CAR RNA was detected in peripheral blood 1–2 hours post-infusion and at no other time point (Figure s3A).”
> “Bone marrow biopsies are not customarily done on MG patients, so bone marrow was not assessed for the presence of CARs or CAR RNA.”
> “In accordance with time-restricted expression of RNA-based CAR molecules in vitro18, mRNA detection in our study was transient.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-2.1.2.6.3-3"></a>

### Circulating CAR RNA after infusion and at month 3: phase 2b

> “Lastly, pharmacokinetic profiling using quantitative real-time polymerase chain reaction (qRT–PCR) revealed large, discrete increases in Descartes-08 RNA levels after infusion that were absent prior to infusion and at later times, such as month 3 (approximately 7 weeks after the final infusion) (n = 19) (Fig. 2f).”
> “Although some changes in cytokines associated with Descartes-08 did not persist at month 12, others, such as IL-6 and RANKL, did persist or did not become evident until this time (EN-RAGE, TRAIL and TNFSF14), even though CAR expression persists only for a period of days.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.3-4"></a>

### CAR expression in circulating T cells one day after infusion in a mouse xenograft model

> “One day after Descartes-08 infusion, CAR expression was detectable in more than 80% of circulating CD45+CD8+ T cells (Fig. 1j–l).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
